Abstract 1785P
Background
Androgen deprivation therapy (ADT) is associated with increased fracture risk, due to bone loss and bone quality impairment, as well as with profound alterations in body composition favoring the transition to sarcopenic obesity. Additional metabolic effects of next generation hormonal agents (NGHA) in combination with ADT have been poorly studied.
Methods
BonEnza (NCT03336983) is a prospective phase II trial in which mHSPC patients were randomized to receive either ADT plus enzalutamide (E arm) or the same combination with the addition of zoledronic acid (EZ arm). Bone mineral density (BMD), trabecular bone score (TBS), fat body mass (FBM) and lean body mass (LBM) were assessed at baseline and after 18 months using dual energy x-ray absorptiometry (DEXA) scan.
Results
From February 2018 to December 2022, a total of 89 patients (46 from EZ arm and 43 from E arm), had paired DEXA evaluation at both timepoints. Femoral BMD and TBS significantly reduced in E arm (-9.1%, p<0.001; -3.1%, p=0.001, respectively), while they increased in EZ arm (5.3%, p<0.001; 2.8%, p=0.008, respectively). FBM increased by 22.7% (p<0.001) and LBM decreased by 6.3% (p<0.001) after 18 months of therapy, irrespective of study arm.
Conclusions
The addition of enzalutamide to ADT is associated with a marked reduction in BMD and impaired bone quality as measured by TBS. Both effects are prevented by zoledronic acid administration. The reduction in LBM and increase in FBM were doubled compared to previous observations with ADT alone, putting patients at an elevated risk of sarcopenic obesity.
Clinical trial identification
NCT03336983.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Astellas.
Disclosure
A. Dalla Volta: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Institutional, Research Funding: Janssen, Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
1816P - Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Presenter: Bertrand Tombal
Session: Poster session 14
1817P - A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care
Presenter: Elan Diamond
Session: Poster session 14
1818P - Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Presenter: Kim van der Zande
Session: Poster session 14
1819P - PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
Presenter: Aline Lara Gongora
Session: Poster session 14